CordIn is under clinical development by Gamida Cell and currently in Phase II for Aplastic Anemia. According to GlobalData, Phase II drugs for Aplastic Anemia have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CordIn’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CordIn is under development for the treatment of hemoglobinopathies including aplastic anemia and hypo-plastic myelodysplastic syndrome. It is administered as an intravenous infusion. The therapeutic candidate is CD133+ cells derived from allogenic umbilical cord blood cells. The drug candidate is developed based on NAM platform technology. It was under development for sickle cell disease and beta thalassaemia.
Gamida Cell overview
Gamida Cell (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia; GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.
For a complete picture of CordIn’s drug-specific PTSR and LoA scores, buy the report here.